 Receptors, Estrogen
"Receptors, Estrogen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
| Descriptor ID |
D011960
|
| MeSH Number(s) |
D12.776.826.750.350 D12.776.930.778.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Estrogen".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Estrogen".
This graph shows the total number of publications written about "Receptors, Estrogen" by people in this website by year, and whether "Receptors, Estrogen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 3 | 3 | | 1995 | 0 | 2 | 2 | | 1996 | 0 | 2 | 2 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 2 | 2 | | 1999 | 2 | 1 | 3 | | 2000 | 3 | 1 | 4 | | 2001 | 1 | 1 | 2 | | 2002 | 0 | 1 | 1 | | 2003 | 2 | 5 | 7 | | 2004 | 2 | 4 | 6 | | 2005 | 1 | 6 | 7 | | 2006 | 2 | 2 | 4 | | 2007 | 4 | 6 | 10 | | 2008 | 8 | 5 | 13 | | 2009 | 1 | 4 | 5 | | 2010 | 5 | 5 | 10 | | 2011 | 2 | 6 | 8 | | 2012 | 6 | 6 | 12 | | 2013 | 2 | 6 | 8 | | 2014 | 4 | 6 | 10 | | 2015 | 4 | 9 | 13 | | 2016 | 10 | 3 | 13 | | 2017 | 6 | 6 | 12 | | 2018 | 4 | 4 | 8 | | 2019 | 1 | 4 | 5 | | 2020 | 3 | 8 | 11 | | 2021 | 7 | 3 | 10 | | 2022 | 0 | 3 | 3 | | 2023 | 2 | 3 | 5 | | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Estrogen" by people in Profiles.
-
Jhaveri KL, Bellet M, Turner NC, Loi S, Bardia A, Boni V, Sohn J, Neilan TG, Villanueva-V?zquez R, Kabos P, Garc?a-Est?vez L, L?pez-Miranda E, P?rez-Fidalgo JA, P?rez-Garc?a JM, Yu J, Fredrickson J, Moore HM, Chang CW, Bond JW, Eng-Wong J, Gates MR, Lim E. Phase Ia/b Study of Giredestrant ? Palbociclib and ? Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer. Clin Cancer Res. 2024 02 16; 30(4):754-766.
-
Hurvitz SA, Bardia A, Quiroga V, Park YH, Blancas I, Alonso-Romero JL, Vasiliev A, Adamchuk H, Salgado M, Yardley DA, Berzoy O, Zamora-Au??n P, Chan D, Spera G, Xue C, Ferreira E, Badovinac Crnjevic T, P?rez-Moreno PD, L?pez-Valverde V, Steinseifer J, Fernando TM, Moore HM, Fasching PA. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2023 09; 24(9):1029-1041.
-
Li Z, Li T, Yates ME, Wu Y, Ferber A, Chen L, Brown DD, Carroll JS, Sikora MJ, Tseng GC, Oesterreich S, Lee AV. The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer. Cancer Res. 2023 08 15; 83(16):2656-2674.
-
Chandarlapaty S, Dickler MN, Perez Fidalgo JA, Villanueva-V?zquez R, Giltnane J, Gates M, Chang CW, Cheeti S, Fredrickson J, Wang X, Collier A, Moore HM, Metcalfe C, Lauchle J, Humke EW, Bardia A. An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2023 08 01; 29(15):2781-2790.
-
Orlicky DJ, Smith EE, Bok R, Guess MK, Rascoff LG, Arruda JS, Hutchinson-Colas JA, Johnson J, Connell KA. Estrogen and Androgen Receptor Status in Uterosacral Ligaments of Women with Pelvic Organ Prolapse Stratified by the Pelvic Organ Prolapse Histology Quantification System. Reprod Sci. 2023 12; 30(12):3495-3506.
-
Frump AL, Yakubov B, Walts A, Fisher A, Cook T, Chesler NC, Lahm T. Estrogen Receptor-a Exerts Endothelium-Protective Effects and Attenuates Pulmonary Hypertension. Am J Respir Cell Mol Biol. 2023 03; 68(3):341-344.
-
Bardia A, Mayer I, Winer E, Linden HM, Ma CX, Parker BA, Bellet M, Arteaga CL, Cheeti S, Gates M, Chang CW, Fredrickson J, Spoerke JM, Moore HM, Giltnane J, Friedman LS, Chow Maneval E, Chan I, Jhaveri K. The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR?+?/HER2?-) advanced/metastatic breast cancer. Breast Cancer Res Treat. 2023 Jan; 197(2):319-331.
-
Liang J, Ingalla ER, Yao X, Wang BE, Tai L, Giltnane J, Liang Y, Daemen A, Moore HM, Aimi J, Chang CW, Gates MR, Eng-Wong J, Tam L, Bacarro N, Roose-Girma M, Bellet M, Hafner M, Metcalfe C. Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer. Sci Transl Med. 2022 09 21; 14(663):eabo5959.
-
Rao S, Han AL, Zukowski A, Kopin E, Sartorius CA, Kabos P, Ramachandran S. Transcription factor-nucleosome dynamics from plasma cfDNA identifies ER-driven states in breast cancer. Sci Adv. 2022 08 26; 8(34):eabm4358.
-
Bianco G, Coto-Llerena M, Gallon J, Kancherla V, Taha-Mehlitz S, Marinucci M, Konantz M, Srivatsa S, Montazeri H, Panebianco F, Tirunagaru VG, De Menna M, Paradiso V, Ercan C, Dahmani A, Montaudon E, Beerenwinkel N, Kruithof-de Julio M, Terracciano LM, Lengerke C, Jeselsohn RM, Doebele RC, Bidard FC, Marangoni E, Ng CKY, Piscuoglio S. GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers. Commun Biol. 2022 04 19; 5(1):373.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|